

Figure S1. Macrophage-like cells in peripheral blood were detected using flow cytometry with a CD45⁺CD1c⁻CD2⁻CD15⁻CD19⁻CD14⁺CD16⁺CD11b⁺ gating strategy. FSC, forward scatter; SSC, side scatter.




Figure S2. Percentages of macrophage-like cells in the peripheral blood of patients with glioma were not significantly different between patients with advanced (stages III and IV) and those with early (stages I and II) glioma. (A) M1 percentages of CD11b^{int} macrophage-like cells in the peripheral blood of patients with glioma were not significantly different between patients with advanced (stages III and IV) and those with early (stages I and II) glioma. (B) M1 percentages of CD11b^{hi} macrophage-like cells in the peripheral blood of patients with glioma were not significantly different between patients with advanced (stages III and IV) and those with early (stages I and II) glioma. (C) M2 percentages of CD11b^{hi} macrophage-like cells in the peripheral blood of patients with glioma were not significantly different between patients with advanced (stages III and IV) and those with early (stages I and II) glioma. n.s., not significant ($P>0.05$); int, intermediate; hi, high.




Figure S3. Percentages of macrophage-like cells were not significantly different between patients with glioma with low YKL-40 expression and those with high YKL-40 expression. (A) M1 percentages of CD11b^{int} macrophage-like cells were not significantly different between patients with glioma with low YKL-40 expression and those with high YKL-40 expression. (B) M1 percentages of CD11b^{hi} macrophage-like cells were not significantly different between patients with glioma with low YKL-40 expression and those with high YKL-40 expression. (C) M2 percentages of CD11b^{hi} macrophage-like cells were not significantly different between patients with glioma with low YKL-40 expression and those with high YKL-40 expression. n.s., not significant ($P>0.05$); int, intermediate.

